litlas
ログインアカウント作成

Tomoki Naoe

1993–2024 年に発表

80
論文数
24,608
被引用数
69
h 指数
80
i10 指数

被引用数

Tomoki Naoe の年別被引用数1981 年: 被引用 1 件1984 年: 被引用 1 件1992 年: 被引用 2 件1994 年: 被引用 1 件1995 年: 被引用 1 件1996 年: 被引用 2 件1997 年: 被引用 11 件1998 年: 被引用 19 件1999 年: 被引用 42 件2000 年: 被引用 39 件2001 年: 被引用 62 件2002 年: 被引用 109 件2003 年: 被引用 108 件2004 年: 被引用 72 件2005 年: 被引用 85 件2006 年: 被引用 76 件2007 年: 被引用 100 件2008 年: 被引用 139 件2009 年: 被引用 174 件2010 年: 被引用 237 件2011 年: 被引用 253 件2012 年: 被引用 229 件2013 年: 被引用 178 件2014 年: 被引用 189 件2015 年: 被引用 152 件2016 年: 被引用 161 件2017 年: 被引用 185 件2018 年: 被引用 191 件2019 年: 被引用 884 件2020 年: 被引用 906 件2021 年: 被引用 780 件2022 年: 被引用 626 件2023 年: 被引用 414 件2024 年: 被引用 569 件2025 年: 被引用 203 件2026 年: 被引用 4 件1982〜1983 年は被引用が無いため表示していません1985〜1991 年は被引用が無いため表示していません1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,547 件、この内訳の 24.8%中国: 引用元論文 1,135 件、この内訳の 11.1%ドイツ: 引用元論文 827 件、この内訳の 8.1%イタリア: 引用元論文 550 件、この内訳の 5.3%イギリス: 引用元論文 536 件、この内訳の 5.2%フランス: 引用元論文 512 件、この内訳の 5%日本: 引用元論文 509 件、この内訳の 5%オランダ: 引用元論文 315 件、この内訳の 3.1%スペイン: 引用元論文 304 件、この内訳の 3%カナダ: 引用元論文 277 件、この内訳の 2.7%オーストラリア: 引用元論文 193 件、この内訳の 1.9%スイス: 引用元論文 186 件、この内訳の 1.8%
0%24.8%その他 23%

機関

分野

  • Medicine63.6%
  • Biochemistry, Genetics and Molecular Biology30.9%
  • Immunology and Microbiology2.5%
  • Agricultural and Biological Sciences0.6%
  • Computer Science0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • その他1.4%

トピック

  • Acute Myeloid Leukemia Research16.7%
  • Acute Lymphoblastic Leukemia research4.8%
  • Chronic Myeloid Leukemia Treatments4.5%
  • MicroRNA in disease regulation4.2%
  • Retinoids in leukemia and cellular processes4%
  • Hematopoietic Stem Cell Transplantation3.6%
  • その他62.2%

共著者

全論文

検索で開く
  1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    著者: Hartmut Döhner, Elihu H. Estey, David Grimwade, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Richard A. Larson, Ross L. Levine, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Hwei‐Fang Tien, Andrew H. Wei, Bob Löwenberg, Clara D. Bloomfield - Blood 2016 被引用: 5,868

  2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

    著者: Hartmut Döhner, Elihu H. Estey, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Alan K. Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A. Larson, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Bob Löwenberg, Clara D. Bloomfield - Blood 2009 被引用: 3,392

  3. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    著者: Miguel Á. Sanz, Pierre Fenaux, Martin S. Tallman, Elihu H. Estey, Bob Löwenberg, Tomoki Naoe, Eva Lengfelder, Hartmut Döhner, Alan K. Burnett, Sai-Juan Chen, Vikram Mathews, Harry Iland, Eduardo Magalhães Rego, Hagop M. Kantarjian, Lionel Adès, Giuseppe Avvisati, Pau Montesinos, Uwe Platzbecker, Farhad Ravandi, Nigel H. Russell, Francesco Lo‐Coco - Blood 2019 被引用: 655

  4. Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

    著者: Keisuke Watanabe, Seitaro Terakura, Anton C. Martens, Tom van Meerten, Susumu Uchiyama, Misa Imai, Reona Sakemura, Tatsunori Goto, Ryo Hanajiri, Nobuhiko Imahashi, Kazuyuki Shimada, Akihiro Tomita, Hitoshi Kiyoi, Tetsuya Nishida, Tomoki Naoe, Makoto Murata - The Journal of Immunology 2014 被引用: 285

  5. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

    著者: Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je‐Hwan Lee, Michael Heuser, Tomoki Naoe, Wen‐Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti‐Passerini, Elżbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Rich, Ramón V. Tiu - Blood 2022 被引用: 126

  6. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

    著者: Takeshi Yamaura, Toshiyuki Nakatani, Ken Uda, Hayato Ogura, Wigyon Shin, Naoya Kurokawa, Koichi Saito, N. Fujikawa, Tomomi Date, Masaru Takasaki, Daisuke Terada, Atsushi Hirai, Akimi Akashi, Fangli Chen, Yoshiya Adachi, Yuichi Ishikawa, Fumihiko Hayakawa, Shinji Hagiwara, Tomoki Naoe, Hitoshi Kiyoi - Blood 2017 被引用: 148

  7. Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS

    著者: Isao Tawara, Shinichi Kageyama, Yoshihiro Miyahara, Hiroshi Fujiwara, Tetsuya Nishida, Yoshiki Akatsuka, Hiroaki Ikeda, Kazushi Tanimoto, Seitaro Terakura, Makoto Murata, Yoko Inaguma, Masahiro Masuya, Naoki Inoue, Tomohide Kidokoro, Sachiko Okamoto, Daisuke Tomura, Hideto Chono, Ikuei Nukaya, Junichi Mineno, Tomoki Naoe, Nobuhiko Emi, Masaki Yasukawa, Naoyuki Katayama, Hiroshi Shiku - Blood 2017 被引用: 168

  8. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

    著者: Takahiko Yasuda, Shinobu Tsuzuki, Masahito Kawazu, Fumihiko Hayakawa, Shinya Kojima, Toshihide Ueno, Naoto Imoto, Shinji Kohsaka, Akiko Kunita, Koichiro Doi, Toru Sakura, Toshiaki Yujiri, Eisei Kondo, Katsumichi Fujimaki, Yasunori Ueda, Yasutaka Aoyama, Shigeki Ohtake, Junko Takita, Eirin Sai, Masafumi Taniwaki, Mineo Kurokawa, Shinichi Morishita, Masashi Fukayama, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, Hiroyuki Mano - Nature Genetics 2016 被引用: 271

  9. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    著者: Miguel Á. Sanz, David Grimwade, Martin S. Tallman, Bob Löwenberg, Pierre Fenaux, Elihu H. Estey, Tomoki Naoe, Eva Lengfelder, Thomas Büchner, Hartmut Döhner, Alan K. Burnett, Francesco Lo‐Coco - Blood 2008 被引用: 957

  10. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11

    著者: Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi - Blood Advances 2020 被引用: 127

  11. Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

    著者: Michinori Ogura, Toshiki Uchida, Yasuhito Terui, Fumihiko Hayakawa, Yukio Kobayashi, Masafumi Taniwaki, Yasushi Takamatsu, Tomoki Naoe, Kensei Tobinai, Wataru Munakata, Takeshi Yamauchi, Akiko Kageyama, Miyuki Yuasa, Masaaki Motoyama, Takeshi Tsunoda, Kiyohiko Hatake - Cancer Science 2015 被引用: 102

  12. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

    著者: Takahiko Yasuda, Masashi Sanada, Masahito Kawazu, Shinya Kojima, Shinobu Tsuzuki, Hiroo Ueno, Eisuke Iwamoto, Yuka Iijima‐Yamashita, Tomomi Yamada, Takashi Kanamori, Rieko Nishimura, Yachiyo Kuwatsuka, Satoru Takada, Masatsugu Tanaka, Shuichi Ota, Nobuaki Dobashi, Etsuko Yamazaki, Asao Hirose, Tohru Murayama, Masahiko Sumi, Shinya Sato, Naoyuki Tange, Yukinori Nakamura, Yuna Katsuoka, Emiko Sakaida, Toyotaka Kawamata, Hiroatsu Iida, Yuichi Shiraishi, Yasuhito Nannya, Seishi Ogawa, Masafumi Taniwaki, Norio Asou, Yoshihiro Hatta, Hitoshi Kiyoi, Itaru Matsumura, Keizo Horibe, Hiroyuki Mano, Tomoki Naoe, Yasushi Miyazaki, Fumihiko Hayakawa - Blood 2021 被引用: 53

  13. EBV-associated T/NK–cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases

    著者: Hiroshi Kimura, Yoshinori Ito, Shinji Kawabe, Kensei Gotoh, Yoshiyuki Takahashi, Seiji Kojima, Tomoki Naoe, Shinichi Esaki, Atsushi Kikuta, Akihisa Sawada, Keisei Kawa, Koichi Ohshima, Shigeo Nakamura - Blood 2011 被引用: 441

  14. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

    著者: Junji Hiraga, Akihiro Tomita, Takumi Sugimoto, Kazuyuki Shimada, Masafumi Ito, Shigeo Nakamura, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe - Blood 2009 被引用: 258

  15. Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients

    著者: Takashi Oyama, Kazuhito Yamamoto, Naoko Asano, Aya Oshiro, Ritsuro Suzuki, Yoshitoyo Kagami, Yasuo Morishima, Kengo Takeuchi, Toshiyuki Izumo, Shigeo Mori, Koichi Ohshima, Junji Suzumiya, Naoya Nakamura, Masafumi Abe, Koichi Ichimura, Yumiko Sato, Tadashi Yoshino, Tomoki Naoe, Yoshie Shimoyama, Yoshikazu Kamiya, Tomohiro Kinoshita, Shigeo Nakamura - Clinical Cancer Research 2007 被引用: 459

  16. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

    著者: Hitoshi Kiyoi, Ryuzo Ohno, Ryuzo Ueda, Hidehiko Saito, Tomoki Naoe - Oncogene 2002 被引用: 283

  17. Microvesicle-mediated RNA Molecule Delivery System Using Monocytes/Macrophages

    著者: Yukihiro Akao, Akio Iio, Tomohiro Itoh, Shunsuke Noguchi, Yuko Itoh, Yoshinori Ohtsuki, Tomoki Naoe - Molecular Therapy 2010 被引用: 242

  18. Thrombosis from a Prothrombin Mutation Conveying Antithrombin Resistance

    著者: Yuhri Miyawaki, Atsuo Suzuki, Junko Fujita, Asuka Maki, Eriko Okuyama, Moe Murata, Akira Takagi, Takashi Murate, Shinji Kunishima, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tomoki Naoe, Hidehiko Saito, Tetsuhito Kojima - New England Journal of Medicine 2012 被引用: 139

  19. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan

    著者: Takashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, Dai Chihara, Takuji Ichihashi, Rika Oshima, Mitsune Tanimoto, Toshihiro Iwasaki, Atsushi Isoda, Akira Sakai, Hikaru Kobayashi, Kunio Kitamura, Kosei Matsue, Masafumi Taniwaki, Sadahiro Tamashima, Yoshio Saburi, Taro Masunari, Tomoki Naoe, Shigeo Nakamura, Tomohiro Kinoshita - Blood 2012 被引用: 135

  20. Adipose Tissue-Derived Mesenchymal Stem Cells Facilitate Hematopoiesis in Vitro and in Vivo

    著者: Norihiko Nakao, Takayuki Nakayama, Takashi Yahata, Yukari Muguruma, Shigeki Saito, Yasuhiko Miyata, Koji Yamamoto, Tomoki Naoe - American Journal Of Pathology 2010 被引用: 133

  21. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

    著者: Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel Á. Sanz, Αchilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee‐Je Kim, Je‐Hwan Lee, Kensuke Usuki, Stefano D’Ardìa, Chul Won Jung, Olga Salamero, Heinz‐August Horst, Christian Récher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valérie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann - HemaSphere 2021 被引用: 29

  22. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

    著者: Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Shigeki Ohtake, June Takeda, Maria Creignou, Lanying Zhao, Manabu Kusakabe, Yuhei Shibata, Nobuhiko Nakamura, Mizuki Watanabe, Nobuhiro Hiramoto, Yusuke Shiozawa, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Yoshida, Nobuyuki Kakiuchi, Hideki Makishima, Masahiro Nakagawa, Kensuke Usuki, Mitsumasa Watanabe, Kazunori Imada, Hiroshi Handa, Masataka Taguchi, Toru Kiguchi, Kazuma Ohyashiki, Takayuki Ishikawa, Akifumi Takaori‐Kondo, Hisashi Tsurumi, Senji Kasahara, Shigeru Chiba, Tomoki Naoe, Satoru Miyano, Elli Papaemanuil, Yasushi Miyazaki, Eva Hellström-Lindberg, Seishi Ogawa - Blood Advances 2023 被引用: 26

  23. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

    著者: Masamitsu Yanada, Jin Takeuchi, Isamu Sugiura, Hideki Akiyama, Noriko Usui, Fumiharu Yagasaki, Tohru Kobayashi, Yasunori Ueda, Makoto Takeuchi, Shuichi Miyawaki, Atsuo Maruta, Nobuhiko Emi, Yasushi Miyazaki, Shigeki Ohtake, Itsuro Jinnai, Keitaro Matsuo, Tomoki Naoe, Ryuzo Ohno - Journal of Clinical Oncology 2005 被引用: 454

  24. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

    著者: The Japan Adult Leukemia Study Group, Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yoshihiro Hatta, Yasuhiko Miyata, Shinichi Kobayashi, Kensuke Usuki, Itaru Matsumura, Yosuke Minami, Noriko Usui, Tetsuya Fukuda, Satoru Takada, Maho Ishikawa, Katsumichi Fujimaki, Hiroshi Gomyo, Osamu Sasaki, Kohshi Ohishi, Takaaki Miyake, Kiyotoshi Imai, Hitoshi Suzushima, Hideki Mitsui, Kazuto Togitani, Toru Kiguchi, Yoshiko Atsuta, Shigeki Ohtake, Kazunori Ohnishi, Yukio Kobayashi, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe - International Journal of Hematology 2017 被引用: 94